The European Medicines Agency announces that blood clotting should be listed as a "very rare" side effect of the Oxford–AstraZeneca vaccine. It also insists that benefits of using the vaccine continue to outweigh the risks. (DW) COVID-19 vaccineCOVID-19 pandemic in EuropeCOVID-19 pandemic link embed save